top of page
Report.png
Vyvgart Market

Vyvgart (Efgartigimod) Market Size, Share, Competitive Landscape and Trend Analysis Report by Indication and Route of Administration: Global Opportunity and Industry Forecast (2025-2030)

Report ID:

1078

Industry:

Healthcare

Published on:

Oct 2025

Vyvgart (Efgartigimod) Market had a value of USD 2.25 Billion in 2024 and expected it to hit USD 5.22 Billion by 2030, with a CAGR of 14.2 % during the forecast period.

Vyvgart (Efgartigimod) Market Overview

The Vyvgart (Efgartigimod) Market represents the commercial environment for medicines based on efgartigimod, a first-in-class monoclonal antibody fragment that targets the neonatal Fc receptor (FcRn). Vyvgart is mainly offered to treat generalized myasthenia gravis (gMG), although it is also being developed for other autoimmune diseases. This medication works by lowering pathogenic immunoglobulin G (IgG) antibodies, which cause disease development in individuals with neuromuscular, immune-mediated diseases. Vyvgart has seen rapid adoption in developed economies with its certification in 2021, particularly among health care workers.

The Vyvgart (Efgartigimod) Market is growing as clinical trials reveal new applications for the drug. In 2024, global prescription volume increased steadily, with hospitals and medical centres reporting an increase in the number of patients transitioning from traditional antibodies to targeted biologics. In 2024, 15,000 patients in North America, Europe, and Asia-Pacific were receive Vyvgart-based care for their illnesses. Changing practice toward more precise medicines, improving results, and safe, long-term steroid sparing all reflect the market's dynamic nature. Pharmaceutical partnerships help to accelerate market growth by making it a recognized therapeutic and improving long-acting oral solutions.

This extensive analysis by Jadhavar Business Intelligence Pvt Ltd provides consumers with a complete and actionable picture of the Global Vyvgart (Efgartigimod) Market, including market size, share, trends, and growth estimates from 2024 to 2030. It provides a complete overview of important locations and countries by Indication, Route of Administration. Clients receive comprehensive market dynamics, business tool analysis (PORTER and PESTLE), a Technology roadmap, and regulatory updates. The study also includes country-specific projections, competitive benchmarking, Company profiles, and M&A activity, all of which aid in strategic planning, market entry analysis, and competitor positioning.

Vyvgart (Efgartigimod) Market Dynamic’s

The increasing number of autoimmune neuromuscular diseases is driving the Vyvgart (Efgartigimod) market. Generalized myasthenia gravis affects around 150,000 people globally, with nearly 80% receiving long-term treatment. With clinical evidence supporting Vyvgart's initial success in reducing antibody levels by about 60% after the first treatment cycle, it has become the preferred medicine among neurologists. Rising medical costs and awareness campaigns have increased medical adoption in the United States and Europe.

Although demand continues to grow, the Vyvgart (Efgartigimod) Market faces some of limitations related to high costs of treatment and restricted accessibility in certain developing countries. The average cost per patient is above USD 200,000 per year, resulting in limits on the availability of treatment outside of the insurance context. However, there are a range of opportunities offered by many clinical trials currently underway investigating various indications, including chronic inflammatory demyelinating polyneuropathy (CIDP) and pemphigus vulgaris. If approvals are provided for these indications, the overall growth of the patient will exceed 50% by 2027.

The Vyvgart (Efgartigimod) Market developed rapidly in 2024, with subcutaneous (SC) injections approved in numerous regions. Clinical trial results demonstrated that the SC formulation worked comparably to intravenous (IV) infusion while requiring 70% less time to administer. Collaboration between Argenx, the developer of Vyvgart, and local pharmaceutical companies has also improved supply chains in Asia-Pacific. Over 1,800 patients were treated with Vyvgart in Japan in 2024, a 35% increase over the previous year.

The future of the Vyvgart (Efgartigimod) Market is driven by innovation and therapeutic advancements. The subcutaneous method of administration, as well as prefilled syringes, will help to improve patient compliance and convenience. The strategic R&D pipeline for several immune-mediated diseases has promising longevity possibilities. By 2028, Vyvgart's global market potential could exceed 50,000 patients per year, strengthening its position in the treatment of autoimmune diseases.

Vyvgart (Efgartigimod) Market Segment Analysis

The Vyvgart Market is segmented into by Indication and Route of Administration.

By Indication

Based on Indication, the Vyvgart Market is segmented into Generalized Myasthenia Gravis (gMG), Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) and Others. In 2024, the gMG segment accounted for 72% of the total Vyvgart (Efgartigimod) Market. The segment's dominance can be due to demonstrated clinical efficacy, strong medical acceptance rates, and a substantial lack of availability in refractory gMG patients. Access to considerable long-term safety data has increased patient and provider confidence in continuing medication. Development into CIDP and other autoimmune illnesses is ongoing, but gMG remains the primary indication for prescription volume and revenue generation.

By Route of Administration

Based on Indication, the Vyvgart Market is segmented into Intravenous (IV) Infusion, Subcutaneous (SC) Injection and Prefilled Syringe. In 2024, the IV Infusion segment held the largest share of the Vyvgart (Efgartigimod) Market, accounting for 65% of the total. This is related to the IV Infusion product's initial regulatory procedure, general availability in hospitals, and treatment infrastructure. Still, the subcutaneous mode of delivery continues to grow as more patients and physicians desire shorter treatment periods and self-administration. Prefilled syringes are also likely to grow in popularity by 2026, as convenience and accessibility are key drivers of therapeutic adoption.

Vyvgart (Efgartigimod) Market Region analysis

North America dominated the Vyvgart (Efgartigimod) Market in 2024, accounting for 48% of the global market share. Early regulatory approval, strong insurance coverage, and advanced healthcare infrastructure have helped the region maintain its market leadership. In addition, campaigns to raise patient knowledge of immune-mediated disorders, participation in clinical trials, and an established and accessible market for biologic medicines in the United States have all resulted in increased adoption rates.

Strong increase was also noticed in the Europe region, which has the second greatest market presence. Germany, France, and the United Kingdom were among the countries evaluated for 2024, with a scheduled 6,000 patients undergoing Vyvgart medication. With supporting regulatory frameworks, government-backed reimbursement, and investments in autoimmune-related research, Europe is an exciting market for the future.

Vyvgart (Efgartigimod) Market Competitive Analysis

Argenx, the original developer of Vyvgart (Efgartigimod), remains the major company driving the Vyvgart Product Market through ongoing product innovation, clinical research, and growth into new product indications. Other collaborations with renowned pharmaceutical companies have resulted in stronger regional supply chains and more patient access. Although competitors are researching similar FcRn-targeting medicines, Vyvgart now has a first-mover advantage in some applications. Argenx is focusing on life-cycle management with subcutaneous formulation and prefilled syringe launches to maintain its market leadership position.

Vyvgart (Efgartigimod) Market Scope:

Vyvgart (Efgartigimod) Market Key Players –

  1. AbbVie Inc.

  2. Roche Holding AG

  3. Pfizer Inc.

  4. Sanofi S.A.

  5. argenx SE

  6. Zai Lab Ltd.

  7. Medison Pharma

  8. Hansoh Pharma

  9. Johnson & Johnson

  10. AstraZeneca plc

  11. Eli Lilly and Company

  12. Novartis AG

  13. Takeda Pharmaceutical Company Limited

  14. UCB Pharma

  15. Amgen Inc. 

Frequently Ask Questions –

1) What is the Vyvgart (Efgartigimod) Market?

Ans - The Vyvgart (Efgartigimod) Market represents the industry landscape for therapies targeting autoimmune disorders using efgartigimod-based treatments.

2) Which indication dominates the Vyvgart (Efgartigimod) Market?

Ans - Generalized Myasthenia Gravis (gMG) dominates the Vyvgart (Efgartigimod) Market, representing the majority of prescriptions in 2024.

3) What routes of administration are available in the Vyvgart (Efgartigimod) Market?

Ans - The Vyvgart (Efgartigimod) Market includes intravenous infusion, subcutaneous injection, and prefilled syringe delivery options.

4) Which region leads the Vyvgart (Efgartigimod) Market?

Ans - In 2024, North America led the Vyvgart (Efgartigimod) Market, supported by strong infrastructure and insurance coverage.

5) Who are the key players in the Vyvgart (Efgartigimod) Market?

Ans - The Vyvgart (Efgartigimod) Market is primarily driven by Argenx, supported by partnerships with regional pharmaceutical companies.

Report Payment

Single User:
$4199
Spreadsheet:
$2900
Corporate User:
$5500
bottom of page